Pardes Biosciences (PRDS) ($90MM market cap) is one other biotech for the basket, this morning the corporate introduced poor medical outcomes, an 85% discount of their workforce and the choice to pursue strategic alternate options. The corporate has a questionable historical past, it was based shortly after the covid pandemic started in 2020 to pursue new therapies for viral ailments that result in pandemics, they entered right into a merger settlement with a SPAC in June 2021 and accomplished the deSPAC course of in December 2021. Fortunately for them, this was earlier than we began seeing heavy belief redemptions, with virtually the entire SPAC money being delivered to Pardes plus a $75MM PIPE funding. Pardes has one asset, Pomotrelvier, a covid remedy that simply failed to satisfy its Part 2 main endpoint, thus triggering the halt of their improvement program. Even when trial was profitable, it looks like society has moved on from covid and the share worth mirrored the skepticism that this could possibly be a industrial product.
What makes Pardes barely extra fascinating is their restricted historical past, in contrast to others, they have not had time to construct up important NOLs (solely have $66MM) that could be enticing to a reverse-merger associate. Pardes additionally would not have a major lease or different main shutdown prices, so whereas a reverse-merger is probably going nonetheless the primary choice, this one could be a powerful candidate for a reasonably clear liquidation. I do surprise once we see a shift in direction of extra liquidations, as we get increasingly more of those pursuing strategic alternate options, there cannot be sufficient reverse-merger offers to go round (we nonetheless have dozens of SPACs doing the identical too).
Of their 8-Ok launched at this time, Pardes disclosed a present money stability of $172.4MM and $5.7MM of severance associated prices to be incurred within the second quarter associated to the workforce discount. For the margin of security swag, I included a yr’s price of G&A, it will not be that prime however ought to give loads of room for unexpected bills. I purchased a small place at this time.
Disclosure: I personal shares of PRDS